• All

Asgard Therapeutics Announces Appointment of Three Members to its Newly Formed Scientific Advisory Board (SAB)

Asgard Therapeutics announces appointment of three members Axel Schambach, MD PhD, Johanna Olweus, MD PhD, and Joshua Brody, MD to its Newly Formed Scientific Advisory Board (SAB).

Read more

Asgard Therapeutics featured at the Nature Biopharm Dealermakers

Asgard Therapeutics was featured at the Nature Biopharma dealmakers new collection, highlighting companies developing innovative cell and gene therapies. Take a closer look at how Asgard’s in-vivo direct reprogramming approach can convert tumor cells into antigen-presenting dendritic cells and turn cold tumors hot.

Read more

Asgard Therapeutics awarded with NLSinvest Award at Nordic Life Science Days 2022

From a collective of 40 selected start-ups, Asgard Therapeutics was awarded the runner-up prize as part of the NLSDays Investment Track.

Read more

Asgard Therapeutics appoints Martin Bonde as Independent Chair of the Board of Directors

Lund, Sweden, 13 September 2022 – Asgard Therapeutics AB (“Asgard”), a private biotech company pioneering...

Read more

Asgard Therapeutics Granted U.S. Patent for Dendritic Cell Reprogramming

Lund, Sweden – 01 June – Asgard Therapeutics AB (“Asgard”) today announces that the United States...

Read more

In-person kick-off meeting of the Eurostars-funded REPRINT

Asgard Therapeutics announces today that the Eurostars-funded project REPRogramming tumors INTo immune cells - a revolutionary gene therapy to treat cancer (REPRINT) - has officially kicked-off.

Read more

Cristiana Pires CEO discusses the increasing traction of cellular reprogramming within the investor community in Portuguese newspaper Expresso.

The world wealthiest look for cellular reprogramming as the key for longevity with limitless funds for research

Read more

Asgard Therapeutics highlighted at the Labiotech article “Investors Flock to Startups Reprogramming Cell Therapies”

“A growing interest in the field and even a fear of missing out on a revolutionary approach.”

Read more
Page 1 of 3